EXHIBIT 10.4

Confidential portions of this exhibit have been omitted because they are both (i) not material and (ii) are the type of information that the registrant treats as private or confidential. The redacted terms have been marked at the appropriate place with “[***].”

MANAKO LABS LTD

SAFE SIDE LETTER AGREEMENT

May 28, 2026

Dear Sir/Madam,

This agreement (this “Agreement”) is entered into in connection with the investment by TAOWEAVE, INC. (the “Investor”) in MANAKO LABS LTD a company incorporated under the laws of England and Wales with registered number 17048521 whose registered office is at 71-75 Shelton Street, Covent Garden, London, United Kingdom, WC2H 9JQ (the “Company”) of that certain simple agreement for future equity between the Investor and the Company dated on or about the date of this Agreement (the “Investor’s Safe”). As a material inducement to the Investor’s investment, and in connection with the Technology License and Distribution Agreement entered into by the Company and the Investor on or about the date hereof (the “TLDA”), the Company agrees to the provisions set forth in this Agreement. Capitalised terms used herein but not otherwise defined shall have the meanings set forth in the Investor’s Safe.

Subject to paragraph 1.2, the Investor shall have the right to subscribe for its pro rata share of Senior Shares being issued in the next Equity Financing (the “Pro Rata Right”) Pro rata share for purposes of this Pro Rata Right is the ratio of (x) the number of Shares issued from the conversion of all of the Investor’s Safe to (y) the Company Capitalisation. The Pro Rata Right described above shall automatically terminate upon the earlier of (i) the Company completing a single Equity Financing in which gross proceeds of $5,000,000 (or equivalent) or more are raised (ii) immediately prior to the closing of a Liquidity Event; or (iii) immediately prior to a Dissolution Event.

The Company shall adopt new financing documents in the next Equity Financing based on the Model Documents for Early Stage Investments published by UK Private Capital (formerly, the BVCA), which shall include a 1x non-participating liquidation preference, broad-based weighted average anti-dilution rights, rights of pre-emption on new issuances and transfers, drag-along rights, tag-along rights and customary investor protective provisions(with the intention that the threshold for approval of such protective provisions will be set so that no one investor or affiliated group of investors shall have a sole veto). Such rights shall be extended to the Investor, subject in each case to (i) the Investor’s liquidation preference and anti-dilution rights being set by reference to the Conversion Price of the Investor’s Safe and not the subscription price paid for Senior Shares (ii) the minimum shareholding requirement (if any) for eligibility for information, pre-emption and co-sale rights agreed in connection with such Equity Financing and (iii) the Investor’s execution of any transaction documents relating to such Equity Financing, including without limitation any shareholders’ agreement relating to the Company executed by the investors subscribing for Senior Shares in such Equity Financing.

For so long as the Investor holds the Investor's Safe or any shares in the capital of the Company, the Company shall provide to the Investor: (a) within 30 days of filing thereof with Companies House, a copy of the Company's annual accounts; (b) within 45 days of the end of each calendar quarter, unaudited management accounts of the Company for such quarter, prepared in accordance with the Company's usual accounting practices and including a profit and loss statement, balance sheet, and cash flow statement; and (c) upon reasonable written request of the Investor (not more than once per calendar quarter), a current capitalisation table of the Company on a fully-diluted basis. The Investor shall keep such information confidential in accordance with the confidentiality provisions of this Agreement.

The Company shall provide written notice to the Investor not less than 90 calendar days prior to any material change of either Max Sebti or Tim Kalic from their respective roles as Chief Executive Officer and Chief Technology Officer of the Company, except where the provision of such notice is precluded by the relevant individual's circumstances or by applicable law (in which case the Company shall provide such notice within 5 business days following any such material change).

The Investor agrees that the Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor or make decisions with respect to its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement, unless such confidential information (i) is known or becomes known to the public in general (other than as a result of a breach of this paragraph 9 by the Investor), (ii) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (iii) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that the Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent reasonably necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any existing or prospective affiliate, partner, member, shareholder, or wholly owned subsidiary of the Investor in the ordinary course of business, provided that the Investor informs such person that such information is confidential and directs such person to maintain the confidentiality of such information; or (iii) as may otherwise be required by law, regulation, rule, court order or subpoena, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed and delivered on the date shown on the first page.